Bishop Stacey Latimer, 63, was diagnosed with metastatic prostate cancer in 2019. He enrolled in a clinical trial and is still going strong.

Meanwhile, across the country, members of the Los Angeles Pink Dragons, trained in the summer for the annual International Dragon Boat festival in Long Beach, California, held in July, and the 10 th ...

John Haanen, MD, PhD, of the Netherlands Cancer Institute in Amsterdam, and colleagues, in collaboration with Ugur Sahin’s team at BioNTech in Germany, tested a novel type of CAR-T therapy that ...

The global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. One in 5 men and one in 6 women worldwide develop cancer during their lifetime, and one in ...

Galleri, a blood test that aims to detect over 50 cancers, illustrates the promise and popularity of an emerging technology to screen for cancer. Although the blood test is not approved by the Food ...

Akiko Hanai of Kyoto University and her colleagues studied peripheral neuropathy prevention in 40 women receiving paclitaxel for breast cancer. The average age was 56. The women wore Elasto-Gel frozen ...

During chemotherapy, 29% of participants in the cooling group developed at least Grade 2 neuropathy in the frozen-glove hand, compared with 50% in the untreated hand. In the compression group, 24% had ...

Researchers from The University of Texas MD Anderson Cancer Center will present new data at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting demonstrating that stereotactic body ...

Luckily, a vast range of skilled and dedicated patient advocates can provide support to people with cancer and their loved ones. They raise funds and awareness, build programs and communities, share ...

Squamous cell skin cancer is the second most common cancer in the United States (after basal cell skin cancer), with an estimated 700,000 new cases diagnosed annually, according to the FDA. CSCC is ...

NCI -supported research led to a series of discoveries that resulted in the development of imatinib (Gleevec), a landmark drug that has vastly improved the outcomes of patients with a type of blood ...

A drawback of CAR-T therapy is that the personalized treatment is labor-intensive and expensive—Yescarta currently costs more than $350,000 for a single infusion—which limits its use for most of the ...